Growing-up hand in hand with robots: Designing and evaluating child-robot interaction from a developmental perspective

Robots are becoming part of children's care, entertainment, education, social assistance and therapy. A steadily growing body of Human-Robot Interaction (HRI) research shows that child-robot interaction (CRI) holds promises to support children's development in novel ways. However, research has shown that technologies that do not take into account children's needs, abilities, interests, and developmental characteristics may have a limited or even negative impact on their physical, cognitive, social, emotional, and moral development. As a result, robotic technology that aims to support children via means of social interaction has to take the developmental perspective into consideration. With this workshop (the third of a series of workshops focusing CRI research), we aim to bring together researchers to discuss how a developmental perspective play a role for smart and natural interaction between robots and children. We invite participants to share their experiences on the challenges of taking the developmental perspective in CRI, such as long-term sustained interactions in the wild, involving children and other stakeholders in the design process and more. Looking across disciplinary boundaries, we hope to stimulate thought-provoking discussions on epistemology, methods, approaches, techniques, interaction scenarios and design principles focused on supporting children's development through interaction with robotic technology. Our goal does not only focus on the conception and formulation of the outcomes in the context of the workshop venue, but also on their establishment and availability for the HRI community in different forms

Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy)

The emergency caused by Covid-19 pandemic raised interest in studying lifestyles and comorbidities as important determinants of poor Covid-19 prognosis. Data on tobacco smoking, alcohol consumption and obesity are still limited, while no data are available on the role of e-cigarettes and heated tobacco products (HTP). To clarify the role of tobacco smoking and other lifestyle habits on COVID-19 severity and progression, we designed a longitudinal observational study titled COvid19 and SMOking in ITaly (COSMO-IT). About 30 Italian hospitals in North, Centre and South of Italy joined the study. Its main aims are: 1) to quantify the role of tobacco smoking and smoking cessation on the severity and progression of COVID-19 in hospitalized patients; 2) to compare smoking prevalence and severity of the disease in relation to smoking in hospitalized COVID-19 patients versus patients treated at home; 3) to quantify the association between other lifestyle factors, such as e-cigarette and HTP use, alcohol and obesity and the risk of unfavourable COVID-19 outcomes. Socio-demographic, lifestyle and medical history information will be gathered for around 3000 hospitalized and 700-1000 home-isolated, laboratory-confirmed, COVID-19 patients. Given the current absence of a vaccine against SARS-COV-2 and the lack of a specific treatment for COVID-19, prevention strategies are of extreme importance. This project, designed to highly contribute to the international scientific debate on the role of avoidable lifestyle habits on COVID-19 severity, will provide valuable epidemiological data in order to support important recommendations to prevent COVID-19 incidence, progression and mortality

Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]

<p>Abstract</p> <p>Background</p> <p>Prevention of preterm birth remains one of the most important challenges in maternity care. We propose a randomised trial with: a simple <it>Candida </it>testing protocol that can be easily incorporated into usual antenatal care; a simple, well accepted, treatment intervention; and assessment of outcomes from validated, routinely-collected, computerised databases.</p> <p>Methods/Design</p> <p>Using a prospective, randomised, open-label, blinded-endpoint (PROBE) study design, we aim to evaluate whether treating women with asymptomatic vaginal candidiasis early in pregnancy is effective in preventing spontaneous preterm birth. Pregnant women presenting for antenatal care <20 weeks gestation with singleton pregnancies are eligible for inclusion. The intervention is a 6-day course of clotrimazole vaginal pessaries (100 mg) and the primary outcome is spontaneous preterm birth <37 weeks gestation.</p> <p>The study protocol draws on the usual antenatal care schedule, has been pilot-tested and the intervention involves only a minor modification of current practice. Women who agree to participate will self-collect a vaginal swab and those who are culture positive for Candida will be randomised (central, telephone) to open-label treatment or usual care (screening result is not revealed, no treatment, routine antenatal care). Outcomes will be obtained from population databases.</p> <p>A sample size of 3,208 women with <it>Candida </it>colonisation (1,604 per arm) is required to detect a 40% reduction in the spontaneous preterm birth rate among women with asymptomatic candidiasis from 5.0% in the control group to 3.0% in women treated with clotrimazole (significance 0.05, power 0.8). Analyses will be by intention to treat.</p> <p>Discussion</p> <p>For our hypothesis, a placebo-controlled trial had major disadvantages: a placebo arm would not represent current clinical practice; knowledge of vaginal colonisation with <it>Candida </it>may change participants' behaviour; and a placebo with an alcohol preservative may have an independent affect on vaginal flora. These disadvantages can be overcome by the PROBE study design.</p> <p>This trial will provide definitive evidence on whether screening for and treating asymptomatic candidiasis in pregnancy significantly reduces the rate of spontaneous preterm birth. If it can be demonstrated that treating asymptomatic candidiasis reduces preterm births this will change current practice and would directly impact the management of every pregnant woman.</p> <p>Trial registration</p> <p>Australian New Zealand Clinical Trials Registry <a href="http://www.anzctr.org.au/ACTRN12610000607077.aspx">ACTRN12610000607077</a></p

Tobacco Worker’s Lung: A Neglected Subtype of Hypersensitivity Pneumonitis

Tobacco worker’s lung (TWL) is a type of hypersensitivity pneumonitis (HP) affecting workers exposed to tobacco leaves and molds in the humidified environment of the tobacco production industry. Limited epidemiological data point to a prevalence of TWL that is not negligible and probably underestimated. As in other types of HP, an acute vs. chronic presentation depends on the pattern of the exposure. Therefore, the clinical presentation can vary from an acute influenza-like syndrome, mostly self-limiting with the removal of the exposure, to an insidious onset of cough, exertional dyspnea, fatigue and weight loss in chronic presentations, where fibrotic changes may be observed. The main treatment strategy is the removal of the exposure to tobacco dust and molds, while the main aim of corticosteroid therapy is to reduce morbidity and prevent complications, namely the development of pulmonary fibrosis and permanent lung dysfunction. Despite the fact that TWL is quite well described, preventive measures are not usually adopted in the tobacco production industry. We present here a state of the art review of this neglected, preventable, but still prevalent and occupational-related subtype of HP

Considerations on the article De Bernardis, E., & Busà, L. (2020). A putative role for the tobacco mosaic virus in smokers’ resistance to COVID-19 Medical Hypotheses, 110153

A putative role for the tobacco mosaic virus in smokers’ resistance to COVID- 19 was supposed by de Bernardis and co-authors. However, there are several issues that need to be addressed: putative “high mortality rate of smokers infected by SARS-CoV-2”, “poor collection of medical history details in an emergency situation”, reverse causation (i.e. smokers with severe symptoms may stop smoking before admission to hospital and therefore be counted as non-smokers; alternatively, people presenting with COVID-19 may be less likely to admit to being current smokers); self-selection (smokers with COVID-19 may be less likely to present to hospital, either because they have died or they self-treat in the community, e.g. because of lack of access to funds, given that smoking has a strong negative association with socio-economic position); cohort effects (smoking prevalence declines with age and older people are more likely to be hospitalised if they are infected). Other authors showed that smoking increases the risk of severe COVID-19 by around two-fold and meta-analyses reported higher prevalence of comorbidities, many of which are tobacco-related diseases, in patients with severe COVID-19 reporting an OR = 2.25 (95% CI: 1.49–3.39) for developing severe Covid-19 among patients with a smoking history. In the light of all these considerations, the validity of the affirmation made by de Bernardis and colleague about the “resistance of tobacco smokers to the SARSCoV-2 infection”, either for infection, or for progression and severity of COVID-19, is not convincing

Tobacco smoking and COVID-19 pandemic. Old and new issues. A summary of the evidence from the scientific literature

Introduction: COVID-19 pandemic burst onto the international scene as a new disease disproportionately affecting certain patient groups; hence it has risen many questions yet to be clarified. The aim of this study was to outline the main issues that led tobacco smoking being discussed as a potential risk factor associated with COVID-19. Methods: Articles from MEDLINE and pre-prints published from January to April 2020 were identified. Results: Data from China showed that men had more severe outcomes of COVID-19 than women. Since smoking prevalence is very high among Chinese men in comparison to women, it was hypothesized that smoking could be a risk factor for poor prognosis. This was also supported by the higher prevalence of comorbidities, many of which tobacco-related diseases, in patients with severe COVID-19, who were also more likely to have a smoking history. A meta-analysis confirmed these results, reporting an OR=2.25 (95% CI: 1.49-3.39) for developing severe COVID-19 among patients with a smoking history. Some authors, noticing that reported smoking prevalence among hospitalized patients was substantially lower than smoking prevalence in the source populations, speculated a protective role of nicotine. However, it is likely that low prevalence among hospitalized patients are partially due to many smokers misclassified as nonsmokers. Tobacco smoking seems to cause a dose-dependent upregulation of angiotensin-convertingenzyme-2 (ACE2), the virus cellular entry receptor, which could explain the higher risk of severe COVID-19 in smokers. Conclusions: There is need for further independent studies to clarify the role of smoking on COVID-19 incidence, progression and mortality